BACKGROUND: The prognostic value of NT-proBNP has been recognized in patients with amyloidosis complicated by cardiac involvement. We aimed to use contrast enhanced cardiac magnetic resonance imaging (CMR) to identify functional and structural alterations related to levels of NT-proBNP better to understand the mechanisms of its release in cardiac amyloidosis. METHODS AND RESULTS: CMR was performed on a 1.5-T scanner in 34 patients with biopsy proven amyloid light chain (AL; n = 27) or hereditary transthyretin related (TTR; n = 7) amyloidosis. NT-proBNP was higher in patients with (n = 25) compared to patients without cardiac involvement (n = 9) (2931 (IQR: 972-8629; min-max: 25-27,277) pg/ml vs. 177 (IQR: 71-1431; min-max: 22-7935) pg/ml, p = 0.008). ROC analysis identified a NT-proBNP of <2426.5 pg/ml as optimal discriminator for event free survival (682 +/- 65 days). NT-proBNP did not correlate with LV- ejection fraction, end-diastolic and end-systolic volumes or stroke volume. There was a moderate correlation between NT-proBNP and LV-mass (R = 0.52, p = 0.003) and extent of late gadolinium enhancement (LGE; R = 0.41, p = 0.04). CONCLUSIONS: This study confirms the prognostic value of NT-proBNP in patients with AL and TTR amyloidosis and provides the novel finding that NT-proBNP correlates with surrogates of myocardial amyloid burden such as LV-mass and LGE, supporting the concept of NT-proBNP as a biomarker reflecting the severity of cardiac amyloid infiltration.
BACKGROUND: The prognostic value of NT-proBNP has been recognized in patients with amyloidosis complicated by cardiac involvement. We aimed to use contrast enhanced cardiac magnetic resonance imaging (CMR) to identify functional and structural alterations related to levels of NT-proBNP better to understand the mechanisms of its release in cardiac amyloidosis. METHODS AND RESULTS: CMR was performed on a 1.5-T scanner in 34 patients with biopsy proven amyloid light chain (AL; n = 27) or hereditary transthyretin related (TTR; n = 7) amyloidosis. NT-proBNP was higher in patients with (n = 25) compared to patients without cardiac involvement (n = 9) (2931 (IQR: 972-8629; min-max: 25-27,277) pg/ml vs. 177 (IQR: 71-1431; min-max: 22-7935) pg/ml, p = 0.008). ROC analysis identified a NT-proBNP of <2426.5 pg/ml as optimal discriminator for event free survival (682 +/- 65 days). NT-proBNP did not correlate with LV- ejection fraction, end-diastolic and end-systolic volumes or stroke volume. There was a moderate correlation between NT-proBNP and LV-mass (R = 0.52, p = 0.003) and extent of late gadolinium enhancement (LGE; R = 0.41, p = 0.04). CONCLUSIONS: This study confirms the prognostic value of NT-proBNP in patients with AL and TTRamyloidosis and provides the novel finding that NT-proBNP correlates with surrogates of myocardial amyloid burden such as LV-mass and LGE, supporting the concept of NT-proBNP as a biomarker reflecting the severity of cardiac amyloid infiltration.
Authors: A Cortese; G Vita; M Luigetti; M Russo; G Bisogni; M Sabatelli; F Manganelli; L Santoro; T Cavallaro; G M Fabrizi; A Schenone; M Grandis; C Gemelli; A Mauro; L G Pradotto; L Gentile; C Stancanelli; A Lozza; S Perlini; G Piscosquito; D Calabrese; A Mazzeo; L Obici; D Pareyson Journal: J Neurol Date: 2016-03-16 Impact factor: 4.849
Authors: Angelos G Rigopoulos; Muhammad Ali; Elena Abate; Abdel-Rahman Torky; Marios Matiakis; Mammad Mammadov; Hannes Melnyk; Alexander Vogt; Renato de Vecchis; Boris Bigalke; Walter Wohlgemuth; Sophie Mavrogeni; Michel Noutsias Journal: Heart Fail Rev Date: 2019-07 Impact factor: 4.214
Authors: Giampaolo Merlini; Violaine Planté-Bordeneuve; Daniel P Judge; Hartmut Schmidt; Laura Obici; Stefano Perlini; Jeff Packman; Tara Tripp; Donna R Grogan Journal: J Cardiovasc Transl Res Date: 2013-10-08 Impact factor: 4.132
Authors: Arnt V Kristen; Stephanie Lehrke; Sebastian Buss; Derliz Mereles; Henning Steen; Philipp Ehlermann; Stefan Hardt; Evangelos Giannitsis; Rupert Schreiner; Uwe Haberkorn; Philipp A Schnabel; Reinhold P Linke; Christoph Röcken; Erich E Wanker; Thomas J Dengler; Klaus Altland; Hugo A Katus Journal: Clin Res Cardiol Date: 2012-05-15 Impact factor: 5.460